HER2-targeted antibodies are designed to bind to the human epidermal growth factor receptor 2 (HER2), a transmembrane protein overexpressed in certain cancers (e.g., breast, gastric). Their structure consists of:
Y-shaped immunoglobulin framework with two heavy chains and two light chains .
Fab regions at the tips responsible for antigen binding via variable domains (VH and VL) .
Fc regions mediating effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) .
| HER2 Antibody Type | Target | Therapeutic Use | Key Features |
|---|---|---|---|
| Trastuzumab (Herceptin) | HER2 | Breast/gastric cancer | Humanized IgG1 |
| Pertuzumab | HER2 | Breast cancer | Human IgG1 |
| Margetuximab | HER2 | Breast cancer | Engineered Fc |
HER2 antibodies are approved for treating HER2-positive cancers. Key findings include:
Trastuzumab improves survival in HER2+ breast cancer when combined with chemotherapy .
Margetuximab enhances ADCC via Fc region mutations (F243L, R292P) .
Bispecific antibodies (e.g., MDX-H210) target HER2 and CD3 to recruit T-cells, showing efficacy in prostate cancer .
Research highlights the role of HER2 antibodies in modulating immune responses:
Phagocytic resistance in Klebsiella pneumoniae (serotypes K1/K2) correlates with capsular polysaccharide (CPS) production, altering cytokine profiles .
Antibody isotypes (IgG/IgM) exhibit time-dependent sensitivity for detecting infections, reaching 96% accuracy 21–35 days post-symptom onset .
The following tables summarize key datasets from studies analyzing HER2 antibodies:
| Antibody | Target | Application | Sensitivity (95% CI) |
|---|---|---|---|
| Trastuzumab | HER2 | Breast cancer | 72.2% (63.5–79.5) |
| MDX-H210 | HER2/CD3 | Prostate cancer | 35% PSA response |
| IgG/IgM (COVID-19) | SARS-CoV-2 | Serology | 91.4% (87.0–94.4) |
KEGG: sce:YLR020C
STRING: 4932.YLR020C
To validate YEH2 antibody specificity, researchers should employ a multi-modal approach:
Knockout controls: Compare wild-type and YEH2-deletion strains via Western blot (WB) to confirm absence of signal in null mutants .
Orthogonal validation: Pair antibody-based detection (e.g., immunofluorescence) with mRNA quantification (qRT-PCR) or tagged protein expression systems.
Cross-reactivity profiling: Test against lysates from yeast strains lacking YEH2 but expressing homologous proteins (e.g., YEH1).
Table 1: Validation parameters for YEH2 antibody (CSB-PA573781XA01SVG)
| Parameter | Methodology | Expected Outcome |
|---|---|---|
| Specificity | WB on ΔYEH2 vs. WT | No band in ΔYEH2 at ~kDa |
| Sensitivity | Serial dilution WB | Linear signal decay down to 10 ng/mL |
| Cross-reactivity | ELISA with YEH1 recombinant protein | <5% binding at 1 μM |
Effective ChIP requires titration across three dimensions:
Antibody dilution series: Test 1:50 to 1:500 ratios in preliminary IP-WB experiments .
Chromatin input adjustment: Balance between 1 μg (low background) and 10 μg (high yield) of sheared DNA-protein complexes.
Competitive blocking: Use 5% non-fat milk with 0.1% Tween-20 to reduce non-specific binding in yeast lysates.
Isotype controls: Rabbit IgG at matching concentrations to identify non-specific binding .
Fixation artifacts: Compare methanol/acetone vs. paraformaldehyde fixation effects on epitope accessibility.
Compartment markers: Co-stain with DAPI (nucleus) or FM4-64 (vacuole) to confirm organelle-specific signals.
Discrepancies often arise from post-transcriptional regulation. A systematic workflow includes:
Half-life determination: Cycloheximide chase assays to measure YEH2 protein turnover rates.
Riboprofiling: Compare ribosome-protected mRNA fragments with total RNA-seq data.
PTM analysis: Use phospho-enrichment kits + mass spectrometry to identify stability-altering modifications.
Table 2: Case study of YEH2 mRNA-protein discordance
| Condition | mRNA (FPKM) | Protein (ppm) | Half-life (min) | Phosphorylation Sites |
|---|---|---|---|---|
| Standard growth | 12.3 ± 1.2 | 8.9 ± 0.7 | 42 ± 5 | S12, T45 |
| Stress (0.3M NaCl) | 14.1 ± 1.5 | 4.2 ± 0.3* | 28 ± 3* | S12-p, T45-p, S89-p |
| *Denotes p<0.05 vs. control |
Integrate these pipelines:
Epitope mapping: Alphafold2-predicted YEH2 structure to visualize antibody-binding regions .
Docking simulations: HADDOCK or ClusPro for antibody-antigen interaction modeling.
Phylogenetic analysis: Ortholog alignment to assess epitope conservation across Saccharomyces species.
Bait vector optimization: Clone YEH2 into pGBKT7 (Gal4 DBD) with truncated AD (residues 768-881) to reduce background .
Autoactivation testing: Plate transformants on -Leu/-Trp/-His/+3-AT (5-25 mM) media.
Quantitative β-gal assays: Measure ONPG hydrolysis rates for interaction strength quantification.
Equation 1: β-gal activity normalization
Pre-absorption: Incubate antibody with HEK293T lysate (30 min, 4°C) to remove anti-mammalian IgGs .
Species-specific secondaries: Use anti-rabbit HRP conjugates pre-adsorbed against human/mouse proteins.
Microfluidic WB: Implement the ProteinSimple Jess system for pg-level detection without transfer artifacts.
Calibration beads: Use Quantum MESF standards to convert fluorescence to molecules/cell.
Internal reference: Co-stain with FITC-conjugated anti-Pgk1 (housekeeping control).
Non-linear regression: Fit data using a four-parameter logistic model:
Where =minimum, =maximum, =EC50, =slope factor.
While YEH2 is Saccharomyces-specific, engineered cross-species applications require:
Epitope tagging: Insert 3×FLAG at the C. albicans YEH2 ortholog C1_13500C.
Phylogenic footprinting: Identify unconserved regions for isoform-specific antibody design.
Single-molecule imaging: dSTORM with Alexa Fluor 647-labeled YEH2 antibody (20 nm resolution).
Barcode tagging: Introduce synonymous SNPs in YEH2 ORF via homology-directed repair.
Sort-seq: FACS isolate cells with antibody signal extremes for guide RNA sequencing.
Analysis pipeline: MAGeCK-VISPR for identifying sgRNAs enriched in false-positive populations.